FG
TAK icon

Fairman Group’s Takeda Pharmaceutical TAK Stock Holding History

Fairman Group’s Portfolio TAK Stock Details TAK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-45
Closed -$659 – 351
2025
Q3 		$659 Hold
45
– – ﹤0.01% 250
2025
Q2 		$711 Hold
45
– – ﹤0.01% 230
2025
Q1 		$596 Hold
45
– – ﹤0.01% 228
2024
Q4 		$596 Hold
45
– – ﹤0.01% 305
2024
Q3 		$640 Hold
45
– – ﹤0.01% 350
2024
Q2 		$595 Hold
45
– – ﹤0.01% 353
2024
Q1 		$625 Hold
45
– – ﹤0.01% 347
2023
Q4 		$642 Buy
+45
New +$638 ﹤0.01% 344

Other funds holding TAK

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fairman Group's TAK Position: Q4 2025 in Review

Fairman Group sold out of Takeda Pharmaceutical (TAK) in Q4 2025, closing a stake of 45 shares — an estimated $659 sold.

Fairman Group first reported a position in TAK in Q4 2023 and held it in 8 quarters. The position peaked at $711 in Q2 2025. 349 funds tracked by Wall St. Rank hold TAK as of Q4 2025.

  • Fairman Group reported no remaining Takeda Pharmaceutical position as of Q4 2025 after selling out during the quarter.
  • Fairman Group sold 45 Takeda Pharmaceutical shares in Q4 2025, an estimated $659.
  • Fairman Group first reported a position in Takeda Pharmaceutical in Q4 2023 and held it in 8 quarters.
  • Fairman Group's Takeda Pharmaceutical position peaked at $711 in Q2 2025.
  • 349 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q4 2025.

Based on Fairman Group's 13F filing for Q4 2025, filed 13 Feb 2026.